lilly announces proof of concept data for neutralizing antibody ly-cov555 in the covid-19 outpatient setting
lilly announces proof of concept data for neutralizing antibody ly-cov555 in the covid-19 outpatient setting
existing lilly medicines are now being studied to understand their potential in treating complications of covid-19, and the company is collaborating with two partner companies to discover novel antibody treatments for covid-19.", "\"these interim data from the blaze-1 trial suggest that ly-cov555, an antibody specifically directed against sars-cov-2, has a direct antiviral effect and may reduce covid-related hospitalizations,\" said daniel skovronsky, m.d., ph.d., lilly's chief scientific officer and president of lilly research laboratories.", 


































"lilly intends to test both single antibody therapy as well as combinations of antibodies (sometimes known as antibody cocktails) as potential therapeutics for covid-19.", "ly-cov555 emerged from the collaboration between lilly and abcellera to create antibody therapies for the prevention and treatment of covid-19.", "lilly has successfully completed enrollment and primary safety assessments of ly-cov555 in a phase 1 study of hospitalized patients with covid-19 (nct04411628) and long-term follow-up is ongoing."


































)